CoChat

Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets

Open access
Gates, Leah A., Gu, Guowei, Chen, Yue, Rohira, Aarti D., Lei, Jonathan T., Hamilton, Ross A., Yu, Yang, Lonard, David M., Wang, Jin, Wang, Shu-Ping, Edwards, David G., Lavere, Philip F., Shao, Jiangyong, Yi, Ping, Jain, Antrix, Jung, Sung Yun, Malovannaya, Anna, Li, Shunqiang, Shao, Jieya, Roeder, Robert G., Ellis, Matthew J., Qin, Jun, Fuqua, Suzanne A. W., O’Malley, Bert W., Foulds, Charles E. · 2018 · Oncogene
Cited by 62

The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.

Abstract

Approximately 75% of breast cancers are estrogen receptor alpha (ERα)-positive and are treatable with endocrine therapies, but often patients develop lethal resistant disease. Frequent mutations (10-40%) in the ligand-binding domain (LBD) codons in the gene encoding ERα (ESR1) have been identified, resulting in ligand-independent, constitutively active receptors. In addition, ESR1 chromosomal translocations can occur, resulting in fusion proteins that lack the LBD and are entirely unresponsive to all endocrine treatments. Thus, identifying coactivators that bind to these mutant ERα proteins may offer new therapeutic targets for endocrine-resistant cancer. To define coactivator candidate targets, a proteomics approach was performed profiling proteins recruited to the two most common ERα LBD mutants, Y537S and D538G, and an ESR1-YAP1 fusion protein. These mutants displayed enhanced coactivator interactions as compared to unliganded wild-type ERα. Inhibition of these coactivators decreased the ability of ESR1 mutants to activate transcription and promote breast cancer growth in vitro and in vivo. Thus, we have identified specific coactivators that may be useful as targets for endocrine-resistant breast cancers.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1038/s41388-018-0284-2

Cites

7 of 7 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 7 references

Cited by

See all 62

Metadata

Authors
Gates, L. A., Gu, G., Chen, Y., Rohira, A. D., Lei, J. T., Hamilton, R. A., Yu, Y., Lonard, D. M., Wang, J., Wang, S.-P., Edwards, D. G., Lavere, P. F., Shao, J., Yi, P., Jain, A., Jung, S. Y., Malovannaya, A., Li, S., Shao, J., Roeder, R. G., Ellis, M. J., Qin, J., Fuqua, S. A. W., O’Malley, B. W., & Foulds, C. E.
Venue
Oncogene
Published
2018-05-11
Volume
37
Issue
33
Pages
4581-4598
ISSN
  • 0950-9232 (ISSN-L)
  • 1476-5594
OpenAlex
W2799436835
Cited by
62
References
7
FWCI
5.27
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets. https://app.cochat.ai/papers/10.1038/s41388-018-0284-2
The paper
Gates, L. A., Gu, G., Chen, Y., Rohira, A. D., Lei, J. T., Hamilton, R. A., Yu, Y., Lonard, D. M., Wang, J., Wang, S.-P., Edwards, D. G., Lavere, P. F., Shao, J., Yi, P., Jain, A., Jung, S. Y., Malovannaya, A., Li, S., Shao, J., . . . Foulds, C. E. (2018). Proteomic profiling identifies key coactivators utilized by mutant ERα proteins as potential new therapeutic targets. Oncogene. https://doi.org/10.1038/s41388-018-0284-2

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.